Outcomes for prostate glands &gt;60 cc treated with low-dose-rate brachytherapy

Pham, Y.D.; Kittel, J. A.; Reddy, Chandana A.; Ciezki, Jay P.; Klein, Eric A.; Stephans, Kevin L.; Tendulkar, Rahul D.

doi:10.1016/j.brachy.2015.12.002

Cited by 5 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…urinary retention) in 6% of our patients. The rates of late grade 3 GU toxicities found in our analysis were similar to those published in other studies that included prostate volumes > 50 cc [ 25 ]. However, Millar et al .…”

Section: Discussionsupporting

confidence: 87%

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Chao

Spencer

Guerrieri

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer.Material and methodsBetween 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation. Follow-up was performed every 3 months for 12 months, then every 6 months over 4 years and included prostate specific antigen evaluation. The biochemical relapse-free survival (BRFS) was defined according to the Phoenix criteria. Acute and late toxicities were documented using the Common Terminology Criteria for Adverse Events version 4.0. The BRFS and OS estimates were calculated using Kaplan-Meier plots. Univariate and multivariate analyses were performed to evaluate outcomes by pre-treatment clinical prognostic factors and radiation dosimetry.ResultsThe median follow-up of all patients was 5.45 years. The 5-year BRFS and OS rates were 95% and 96%, respectively. The BRFS rates for patients with Gleason score (GS) > 7 and GS ≤ 6 were 96% and 91% respectively (p = 0.06). On univariate analysis, T1 and T2 staging, risk-group classification, and prostate volumes had no impact on survival at 5 years (p > 0.1). Late grade 2 and 3 genitourinary (GU) toxicities were observed in 10% and 5% of patients respectively. Additionally, patients with prior TURP had a greater incidence of late grade 2 or 3 urinary retention (p = 0.001). There were 14 deaths in total; however, none were attributed to prostate cancer.ConclusionsLDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients.

show abstract

Section: Discussionsupporting

confidence: 87%

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Chao

Spencer

Guerrieri

et al. 2018

jcb

View full text Add to dashboard Cite

show abstract

“…Pham et al. examined toxicity in 2076 men who received BT and subdivided them into those with prostate glands > or <60 mL. With a median follow‐up of 55 months, those with larger glands had more Grade 2 genitourinary toxicity (7.2% vs 3.2%, P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…When stratified by size, Niehaus et al [16] found an increase in temporary urinary catheter requirement with larger glands but eventual normalisation of AUASS for all groups. Pham et al [17] examined toxicity in 2076 men who received BT and subdivided them into those with prostate glands > or <60 mL. With a median follow-up of 55 months, those with larger glands had more Grade 2 genitourinary toxicity (7.2% vs 3.2%, P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…In all, 1 842 men with T1-T3 prostate cancer were treated by BT and followed for a minimum of 5 years (mean 9.4, range [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] and completed a pre-treatment AUASS. Of these, 1110 (60.3%) had minimal urinary symptoms (AUASS 0-7).…”

Section: Methodsmentioning

confidence: 99%

“…In all, 1842 men had completed both the initial pre-implantation and last AUASS assessment. A total of 1110 (60.3%) men had minimal initial urinary symptoms (AUASS of 0-7), 641 (34.8%) moderate symptoms (AUASS of [8][9][10][11][12][13][14][15][16][17][18][19] and 91 (4.9%) severe symptoms (AUASS of 20-35). The QOL score was 0-2 in 1420 (77.1%) men, 3 in 254 (13.8%), and 4-6 in 168 (9.1%).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations